SCHEMBL2980367

SCHEMBL2980367

C#CCOC(=O)N1CC[CH]CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
CHRM1 P11229 1/20 0.42
NFKB1 P19838 1/20 0.42
CHRM3 P20309 1/20 0.42
THPO P40225 1/20 0.42
LMNA P02545 2/20 0.41
PMP22 Q01453 1/20 0.41
NPC1 O15118 2/20 0.38
GAA P10253 2/20 0.35
POLB P06746 3/20 0.35
TSHR P16473 1/20 0.34
ALDH1A1 P00352 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
RAB9A P51151 1/20 0.33
HTT P42858 1/20 0.33
MAPT P10636 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4275238 0.86 ALDH1A1 (0.42) CYP1A2CYP2D6CHRM2CHRM4CHRM5
SCHEMBL12347952 0.82 ALDH1A1 (0.40) CYP1A2CYP2D6CHRM2CHRM4CHRM5
SCHEMBL1713618 0.82 P2RY12 (0.38) CYP1A2CYP2D6CHRM2CHRM4CHRM5
SCHEMBL23254247 0.81 ALDH1A1 (0.42) CYP1A2CYP2D6CHRM2CHRM4CHRM5
SCHEMBL4614113 0.78 CYP1A2 (0.36) CYP1A2CYP2D6CHRM2CHRM4CHRM5
SCHEMBL21722426 0.78 CHRNB2 (0.41) CYP1A2CYP2D6CHRM2CHRM4CHRM5
SCHEMBL21664800 0.78 CYP1A2 (0.45) CYP1A2CYP2D6CHRM2CHRM4CHRM5
SCHEMBL4817856 0.78 TSHR (0.59) CYP1A2LMNAPOLBTSHRALDH1A1
SCHEMBL21205899 0.76 CYP1A2 (0.38) CYP1A2CYP2D6CHRM2CHRM4CHRM5
SCHEMBL18587334 0.76 GAA (0.45) CYP1A2CYP2D6CHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786107-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-08-31 US claimed
EP-2040706-A2 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmceuticals Incorporated (US) 2009-04-01 EP claimed
US-20080033002-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2008-02-07 US claimed
WO-2008005295-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-01-10 WO claimed
US-7858790-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-28 US disclosed
US-7786107-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-08-31 US disclosed
US-20100063021-A9 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2010-03-11 US disclosed
EP-2051715-A2 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmceuticals Incorporated (US) 2009-04-29 EP disclosed
EP-2040706-A2 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmceuticals Incorporated (US) 2009-04-01 EP disclosed
US-20080113958-A1 Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings VERTEX PHARMACEUTICALS INCORPORATED 2008-05-15 US disclosed
WO-2008021545-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-02-21 WO disclosed
US-20080033002-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2008-02-07 US disclosed
WO-2008005295-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063021-A9 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 CYP1A2 1140/4885CYP2D6 1646/4885CHRM2 3/4885
US-20080113958-A1 Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; compounds based on amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings HRH2, ACHE, CHRM2 CYP1A2 897/4885CYP2D6 662/4885CHRM2 3/4885
US-20080033002-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 CYP1A2 1140/4885CYP2D6 1646/4885CHRM2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.